mFOLFOX regimen: Clinical Trials

3 trials of mFOLFOX regimen, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 unknown, 1 not yet recruiting. 2 Phase 3, 1 Early Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 32Not yet recruiting 1, Unknown 1
Early Phase 11Unknown 1
Phase 21Not yet recruiting 1

Follow mFOLFOX regimen: new trials by email Literature Review of mFOLFOX regimen trials Research Report on mFOLFOX regimen

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers
mFOLFOX regimen, Mitazalimab - Biliary Tract Cancer (BTC)
Phase 2 / Phase 3Not yet recruitingUNICANCER1602026-07-012026-02-27
Lenvatinib Plus HAIC of Modified FOLFOX Regime vs Lenvatinib Plus HAIC of ROX Regime in Patients With Advanced HCC
Lenvatinib, mFOLFOX regimen, ROX regimen - Hepatocellular Carcinoma Stage IIIa
Early Phase 1UnknownZhejiang Cancer Hospital602021-07-012021-08-16
mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS Mutant Unresectable Colorectal Liver-limited Metastases
mFOLFOXIRI regimen, mFOLFOX regimen, Bevacizumab - Colorectal Carcinoma, Liver Metastases
Phase 3UnknownFudan University3082021-04-152021-09-27

Conditions studied

Biliary Tract Neoplasms (1)  ·  Carcinoma, Hepatocellular (1)  ·  Colorectal Neoplasms (1)

Sponsors

Fudan University (1)  ·  UNICANCER (1)  ·  Zhejiang Cancer Hospital (1)

Countries

China (2)  ·  France (1)

Top investigators

Jianmin Xu, MD, Ph.D. (1)  ·  Jiaping Zheng, Doctor (1)

Results publications

PMID 19095497, PMID 25027973, PMID 26674592, PMID 27918777, PMID 29471013, PMID 30207593, PMID 30220234, PMID 30959462, PMID 31063184, PMID 31070690, PMID 32497895